Aarti Pharmalabs Limited
₹873.65-₹53.90 (-5.8%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹6,923 Cr
- P/E
- 28.3x
- EV / EBITDA
- 19.5x
- Revenue
- ₹1,771 Cr
- Net margin
- 13.4%
- ROCE
- 18.3%
Price chart
Technical chartScreen technicals →+4.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -8.3%
- 3M
- +29.6%
- 6M
- +17.4%
- 1Y
- +4.7%
- 5Y
- +184.3%
52-week range
Day change -₹53.90 (-5.8%) from ₹928 to ₹874 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in AARTIPHARM, bought on each weekday since 2023.
AI Summary
Indian StockStrengths1
- Revenue grew 17.9% YoY
Concerns1
- Negative free cash flow (₹80 Cr)
Rule-based from financial data. Not advice.
About the company
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally.
Read moreShow less
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for drug substance projects. In addition, the company offers intermediates; xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline; and acid and allied products, including sulphuric acid, sulphur trioxide, oil, dimethyl sulphate, diethyl sulphate, and sodium vinyl sulfonate. The company was formerly known as Aarti Organics Limited. Aarti Pharmalabs Limited was incorporated in 2019 and is headquartered in Mumbai, India.
- Sector
- Healthcare
- Shares outstanding
- 9.0 Cr shares
- ISIN
- INE0LRU01027
- BSE code
- 543748
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹6,923 Cr
- P/E
- 28.3x
- P/B
- 3.6x
- EV / EBITDA
- 19.5x
- EV / Sales
- 4.6x
- P/S
- 4.6x
- Earnings yield
- 3.5%
- 52-week high
- ₹974.65
- 52-week low
- ₹589.25
Profitability
- Operating margin
- 23.0%
- Net margin
- 13.4%
- EBITDA margin
- 23.8%
- ROE
- 12.4%
- ROCE
- 18.3%
- ROA
- 8.8%
- Dividend payout
- 14.0%
- Tax rate
- 27.0%
- Other income, % of PBT
- 4.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹1,771 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 17.9%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹357 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 15.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 27.9%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹184 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -14.8%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹1.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 16.2%
Solvency and efficiency
- Current ratio
- 2.99
- Debt / Equity
- 0.17
- Debt / Assets
- 0.12
- Debt / EBITDA
- 0.76
- Interest coverage
- 20.35
- Financial leverage
- 1.42
- CFO / Net profit
- 0.92
- Cash / Market cap
- 16.5%
- Cash per share
- ₹126.52
- Asset turnover
- 0.65
- Fixed asset turnover
- 1.58
- Capital intensity
- 0.63
- Debtor days
- 109 days
- Inventory turnover
- 1.29
- Cash conversion cycle
- 268 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹15 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹1,344 Cr |
| Sales | Operating profit | ₹427 Cr |
| Operating profit | Interest | ₹26 Cr |
| Operating profit | Depreciation | ₹79 Cr |
| Operating profit | Profit before tax | ₹322 Cr |
| Other income | Profit before tax | ₹14 Cr |
| Profit before tax | Tax and other | ₹79 Cr |
| Profit before tax | Net profit | ₹257 Cr |
Revenue and net profit
Revenue grew 17.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹0 Cr | ₹0 Cr |
| FY2022 | ₹941 Cr | ₹107 Cr |
| FY2023 | ₹1,511 Cr | ₹172 Cr |
| FY2024 | ₹1,502 Cr | ₹201 Cr |
| FY2025 | ₹1,771 Cr | ₹257 Cr |
Cash flows
FY2025: ₹340 Cr from operations, -₹80.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹0 Cr | ₹0 Cr |
| FY2022 | -₹65 Cr | -₹199 Cr |
| FY2023 | ₹216 Cr | ₹100 Cr |
| FY2024 | ₹184 Cr | ₹0 Cr |
| FY2025 | ₹340 Cr | -₹80 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹1,771 Cr+17.9%1Y
- Net profit
- ₹257 Cr+27.9%1Y
- Cash from operations
- ₹340 Cr
- Free cash flow
- -₹80 Cr
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹1,771 Cr | ₹427 Cr | — | ₹257 Cr | ₹340 Cr | -₹80 Cr | 13.9% | +17.9% | +27.9% |
Monthly returns
Month-by-month returns of AARTIPHARM across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹2,724 Cr |
| Equity capital | ₹45 Cr |
| Reserves | ₹1,799 Cr |
| Borrowings | ₹411 Cr |
| Other liabilities | ₹468 Cr |
| Assets | ₹2,724 Cr |
| Fixed assets | ₹1,059 Cr |
| Capital work in progress | ₹369 Cr |
| Investments | ₹57 Cr |
| Other assets | ₹1,239 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
AARTIPHARM trades at 28.3x earnings against a peer median of 52.6x (a 46% discount).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Aarti Pharmalabs LimitedAARTIPHARMthis companyP/E ↓ discount | ₹6,923 Cr | 28.3x | 3.6x | 12.4% | 19.5x |
| Marksans Pharma Ltd.MARKSANS | ₹7,873 Cr | 32.7x | 5.3x | 11.0% | 38.1x |
| Sudeep Pharma LimitedSUDEEPPHRM | ₹7,027 Cr | 73.5x | — | 29.3% | 49.9x |
| Akums Drugs and Pharmaceuticals LimitedAKUMS | ₹6,983 Cr | 50.9x | 2.9x | -114.6% | -133.2x |
| PARK MEDI WORLD LIMITEDPARKHOSPS | ₹6,504 Cr | 906.0x | — | 7.0% | 214.8x |
| FDC Ltd.FDC | ₹6,387 Cr | 27.0x | 2.6x | 14.6% | 14.2x |
| YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITEDYATHARTH | ₹6,186 Cr | 67.3x | 3.9x | 10.0% | 45.5x |
| Kovai Medical Center & Hospital LtdKOVAI | ₹6,071 Cr | 26.6x | 5.1x | 20.2% | 17.2x |
| Supriya Lifescience LimitedSUPRIYA | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
AARTIPHARM since 1 January, against earlier years.
Historical volatility
AARTIPHARM's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 19.0% |
| FY2023 | 20.0% |
| FY2024 | 23.0% |
| FY2025 | 24.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹1,771 Cr |
| Costs | |
| Interest | ₹26 Cr |
| Expenses | ₹1,345 Cr |
| Operating profitOperating Profit | ₹427 Cr |
| Other income and charges | |
| Profit before tax | ₹336 Cr |
| Tax | |
| Net profitNet Profit | ₹257 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹2,724 Cr |
| Equity capitalEquity Capital | ₹45 Cr |
| Reserves | ₹1,799 Cr |
| Borrowings | ₹411 Cr |
| Other liabilitiesOther Liabilities | ₹468 Cr |
| AssetsTotal Assets | ₹2,724 Cr |
| Fixed assetsFixed Assets | ₹1,059 Cr |
| Capital work in progressCWIP | ₹369 Cr |
| Investments | ₹57 Cr |
| Other assetsOther Assets | ₹1,239 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹340 Cr |
| Investing cash flowCash from Investing Activity | -₹420 Cr |
| Financing cash flowCash from Financing Activity | ₹79 Cr |
| Change in cashNet Cash Flow | -₹1 Cr |
Learn while you research
Academy chapters picked for Aarti Pharmalabs Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read